Welcome to the inaugural episode of the No Pill Podcast, hosted by Andrew Hoffman, formerly of the Revelations Radio News Podcast. In this episode, we delve into a recent clip from Larry Ellison discussing the potential of AI in developing cancer vaccines. While the promises sound groundbreaking, I explore the skepticism surrounding these claims, particularly focusing on the mRNA technology and its challenges.

We take a critical look at Moderna, a leading company in mRNA technology, examining its past struggles and current market performance. Despite the hype, Moderna's stock has faced significant declines, and the company is grappling with issues such as vaccine pricing, patent violations, and regulatory failures. I discuss why I remain bearish on mRNA technology and why AI might not be the silver bullet for Moderna's challenges.

We also revisit historical concerns about mRNA delivery systems, particularly the safety issues associated with lipid nanoparticles. These concerns were prevalent before the COVID-19 pandemic and remain unresolved. I question the viability of massive investments in AI-driven cancer vaccines and ponder whether these initiatives are genuine or serve other purposes.

Join me as I navigate through these complex topics, offering insights and raising questions about the future of mRNA technology and its implications. Thank you for tuning in to this first episode, and I look forward to exploring more in future episodes.